Please login to the form below

Not currently logged in
Email:
Password:

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.

The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder. 

Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.

6th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a team outstanding healthcare communications experts who provide innovative strategic evidence based solutions through scientific and commercial...

Latest intelligence

Artificial Intelligence: the new healthcare algorithm
The age of computers has hugely evolved, and with the emergence of effective machine learning, pattern recognition, and decision-making algorithms, Artificial Intelligence provides a revolutionary new approach to tailored healthcare....
Choosing destiny
As our market transforms, firms must choose their new business model carefully...
Market access improvements in Turkey
...

Infographics